MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
Healthcare
$53.42 -1.54%
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
52W Low $9.43High $45.85
Volume 0.73M
Average 0.65M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$98.06M
FY 2025 · Annual
Net Income
-$86.97M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| 31.85M | 31.85M | 33.39M | 36.51M | |
| 31.85M | 31.85M | 33.39M | 36.51M |
MBX Earnings Waterfall · TTM
NASDAQ:MBX · Revenue to Net Income
Key Ratios
EPS$-3.06
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-15.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$145.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.06, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-8 | S-8 filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 |
How much revenue does MBX generate?
MBX Biosciences, Inc. Common Stock (MBX) reported $0.00 of revenue in fiscal 2025.
Is MBX profitable?
MBX Biosciences, Inc. Common Stock (MBX) reported -$86.97M of net income.
Continue the stock analysis
Jump to another research area for this company.